UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis

PLoS neglected tropical diseases, 2023-11, Vol.17 (11), p.e0011795-e0011795

2023

Volltextzugriff (PDF)

Manganese exposure in juvenile C57BL/6 mice increases glial inflammatory responses in the substantia nigra following infection with H1N1 influenza virus

PloS one, 2021-01, Vol.16 (1), p.e0245171

2021

Volltextzugriff (PDF)

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response

PLoS neglected tropical diseases, 2017-01, Vol.11 (1), p.e0005209

2017

Volltextzugriff (PDF)

A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection

Frontiers in immunology, 2022-02, Vol.13, p.811430

2022

Volltextzugriff (PDF)

Targeting intracellular nontuberculous mycobacteria and M. tuberculosis with a bactericidal enzymatic cocktail

Microbiology spectrum, 2024-05, Vol.12 (5), p.e0353423-e0353423

2024

Volltextzugriff (PDF)

Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei

PLoS neglected tropical diseases, 2016-10, Vol.10 (10), p.e0005065

2016

Volltextzugriff (PDF)

Toxin–antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis

Pathogens and disease, 2018-06, Vol.76 (4)

2018

Volltextzugriff (PDF)

The Burkholderia pseudomallei Enoyl-Acyl Carrier Protein Reductase FabI1 Is Essential for In Vivo Growth and Is the Target of a Novel Chemotherapeutic with Efficacy

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.931-935

2014

Volltextzugriff (PDF)

Francisella tularensis FabI Enoyl-Acyl Carrier Protein Reductase Gene Is Essential to Bacterial Viability and Is Expressed during Infection

Journal of Bacteriology, 2013-01, Vol.195 (2), p.351-358

2013

Volltextzugriff (PDF)

Substituted Diphenyl Ethers as a Novel Chemotherapeutic Platform against Burkholderia pseudomallei

Antimicrobial Agents and Chemotherapy, 2014-03, Vol.58 (3), p.1646-1651

2014

Volltextzugriff (PDF)

Discovery of a novel type IIb RelBE toxin‐antitoxin system in Mycobacterium tuberculosis defined by co‐regulation with an antisense RNA

Molecular microbiology, 2022-06, Vol.117 (6), p.1419-1433

2022

Volltextzugriff (PDF)

Rational design of a new antibiotic class for drug-resistant infections

Nature (London), 2021-09, Vol.597 (7878), p.698-702

2021

Volltextzugriff (PDF)

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model

Antimicrobial agents and chemotherapy, 2024-07, Vol.68 (7)

2024

Volltextzugriff (PDF)

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Journal of medicinal chemistry, 2021-10, Vol.64 (20), p.15214-15249

2021

Volltextzugriff (PDF)

Improved non-redundant species screening panels for benchmarking the performance of new investigational antibacterial candidates against Category A and B priority pathogens

JAC-antimicrobial resistance, 2022-04, Vol.4 (2), p.dlac028-dlac028

2022

Volltextzugriff (PDF)

Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor

The Journal of biological chemistry, 2014-06, Vol.289 (23), p.15987-16005

2014

Volltextzugriff (PDF)

Benzimidazole-based antibacterial agents against Francisella tularensis

Bioorganic & medicinal chemistry, 2013-06, Vol.21 (11), p.3318-3326

2013

Volltextzugriff (PDF)

Thiolactomycin-Based Inhibitors of Bacterial β‑Ketoacyl-ACP Synthases with in Vivo Activity

Journal of medicinal chemistry, 2016-06, Vol.59 (11), p.5377-5390

2016

Volltextzugriff (PDF)

TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis

JAC-antimicrobial resistance, 2021-06, Vol.3 (2), p.dlab058-dlab058

2021

Volltextzugriff (PDF)

Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase

Biochemistry (Easton), 2017-04, Vol.56 (13), p.1865-1878

2017

Volltextzugriff (PDF)

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis

Tuberculosis (Edinburgh, Scotland), 2016-12, Vol.101, p.8-14

2016

Volltextzugriff (PDF)

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

Journal of antimicrobial chemotherapy, 2011-03, Vol.66 (3), p.564-573

2011

Volltextzugriff (PDF)

Aggregation and hemi-fusion of anionic vesicles induced by the antimicrobial peptide cryptdin-4

Biochimica et biophysica acta, 2007-07, Vol.1768 (7), p.1796-1804

2007

Volltextzugriff (PDF)

Kinetics of Cryptdin-4 Translocation Coupled with Peptide-Induced Vesicle Leakage

Biochemistry (Easton), 2007-10, Vol.46 (42), p.11882-11891

2007

Volltextzugriff (PDF)

Matrix metalloproteinase-7 activation of mouse paneth cell pro-alpha-defensins: SER43 down arrow ILE44 proteolysis enables membrane-disruptive activity

The Journal of biological chemistry, 2006-09, Vol.281 (39), p.28932-28942

2006

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(139)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis

Manganese exposure in juvenile C57BL/6 mice increases glial inflammatory responses in the substantia nigra following infection with H1N1 influenza virus

Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response

A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection

Targeting intracellular nontuberculous mycobacteria and M. tuberculosis with a bactericidal enzymatic cocktail

Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei

Toxin–antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis

The Burkholderia pseudomallei Enoyl-Acyl Carrier Protein Reductase FabI1 Is Essential for In Vivo Growth and Is the Target of a Novel Chemotherapeutic with Efficacy

Francisella tularensis FabI Enoyl-Acyl Carrier Protein Reductase Gene Is Essential to Bacterial Viability and Is Expressed during Infection

Substituted Diphenyl Ethers as a Novel Chemotherapeutic Platform against Burkholderia pseudomallei

Discovery of a novel type IIb RelBE toxin‐antitoxin system in Mycobacterium tuberculosis defined by co‐regulation with an antisense RNA

Rational design of a new antibiotic class for drug-resistant infections

Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5‑Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA

Improved non-redundant species screening panels for benchmarking the performance of new investigational antibacterial candidates against Category A and B priority pathogens

Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor

Benzimidazole-based antibacterial agents against Francisella tularensis

Thiolactomycin-Based Inhibitors of Bacterial β‑Ketoacyl-ACP Synthases with in Vivo Activity

TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis

Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase

Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

Aggregation and hemi-fusion of anionic vesicles induced by the antimicrobial peptide cryptdin-4

Kinetics of Cryptdin-4 Translocation Coupled with Peptide-Induced Vesicle Leakage

Matrix metalloproteinase-7 activation of mouse paneth cell pro-alpha-defensins: SER43 down arrow ILE44 proteolysis enables membrane-disruptive activity

Suchergebnisse filtern